FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Clears Xtant Medical Irix-C Cervical Cage

FDA clears a Xtant Medical Holdings 510(k) for the Irix-C cervical cage for use with autograft or allograft and the expansion of the range of levels a...

Greenleaf Health Brings on 2 Former FDA Officials

Regulatory consulting firm Greenleaf Health hires two former senior FDA officials former Office of Regional Operations director David Elder and forme...

FDA General

FDA, Others Warned on Finalizing Regs Before Trump in Office

House Republican leaders write FDA commissioner Robert Califf and other federal agency heads to caution them against finalizing pending rules or regul...

Medical Devices

Draft FDA Software Guidance Raises Questions

Two Morgan, Lewis attorneys outline questions and concerns raised by a recent FDA draft guidance on clinical evaluation of software as a medical devic...

Human Drugs

Progress Seen in Pediatric Studies

Experts surveyed to update a Tufts Center for the Study of Drug Development report on pediatric drug studies see efforts moving in the right direction...

CGMP Violations Found in Japans Sekisui Medical

FDA warns Japans Sekisui Medical Co. about CGMP and data integrity issues in its manufacturing of active pharmaceutical ingredients.

FDA General

FTC Enforcement Policy on OTC Homeopathic Drug Claims

The Federal Trade Commission announces a new Enforcement Policy Statement on Marketing Claims for Over-the-Counter (OTC) Homeopathic Drugs.

Patient Advocates Help Develop Rare Disease Products

Contract research organization executives at Premier Research discuss ways in which patient advocates play a lead role with FDA and industry in develo...

Device Recalls Up, Drugs Down: Stericycle

Stericycles third quarter recall index shows an increase in medical device recalls and a decrease in pharmaceutical recalls.

Human Drugs

Drug Warning Letters More than Doubled in 2016: Analysis

An Unger Consulting analysis finds that the number of FDA GMP Warning Letters more than doubled from FY 2015 to FY 2016.